文献速递基础与转化研究流行病学与生物统计临床试验与 GCP

整合临床试验荟萃分析与人类遗传学证据评估硬骨抑素抑制的心血管安全性

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.
PubMed 文献 · Sci Transl Med · 2020-01-01

该研究对罗莫佐单抗(romosozumab)随机对照试验的心血管结局数据进行荟萃分析,并利用模拟治疗性抑制硬骨抑素的SOST基因变异进行遗传学分析。结果显示,罗莫佐单抗与心血管事件风险升高相关,SOST基因变异与骨折和骨质疏松风险降低及心肌梗死、冠脉血运重建和主要不良心血管事件风险升高相关。

要点

  • 罗莫佐单抗的随机对照试验荟萃分析提示心血管事件风险可能升高。
  • 模拟硬骨抑素抑制的SOST基因变异与骨折风险降低及心血管风险升高相关。
  • 需对罗莫佐单抗及其他硬骨抑素抑制剂的心血管安全性进行严格评估。

核心结论

  • 抑制硬骨抑素可能升高心血管风险,需对罗莫佐单抗及其他硬骨抑素抑制剂进行严格心血管安全性评估。

研究设计与样本

  • 对已发表和未发表的罗莫佐单抗心血管结局试验数据进行荟萃分析,最多纳入三项随机对照试验。
  • 利用模拟治疗性抑制硬骨抑素的SOST基因变异进行人类遗传学分析。

主要发现

  • 罗莫佐单抗随机对照试验的荟萃分析提示心血管事件风险可能升高。
  • 按罗莫佐单抗等效剂量(210毫克每月;骨密度高0.09克每平方厘米)折算,SOST基因变异与骨折和骨质疏松风险降低相关,且与心肌梗死和/或冠状动脉血运重建及主要不良心血管事件风险升高相关。
  • 同一SOST基因变异还与2型糖尿病风险升高、收缩压升高和中心性肥胖增加相关。

关键数值与推荐

  • 罗莫佐单抗等效剂量为210毫克每月,对应骨密度高0.09克每平方厘米。

临床怎么用

  • 在临床使用罗莫佐单抗及其他硬骨抑素抑制剂时,应关注并评估患者的心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romosozumab and investigate whether genetic variants that mimic therapeutic inhibition of sclerostin are associated with higher risk of cardiovascular disease. Meta-analysis of up to three RCTs indicated a probable higher risk of cardiovascular events with romosozumab. Scaled to the equivalent dose of romosozumab (210 milligrams per month; 0.09 grams per square centimeter of higher bone mineral density), the SOST genetic variants were associated with lower risk of fracture and osteoporosis (commensurate with the therapeutic effect of romosozumab) and with a higher risk of myocardial infarction and/or coronary revascularization and major adverse cardiovascular events. The same variants were also associated with increased risk of type 2 diabetes mellitus and higher systolic blood pressure and central adiposity. Together, our findings indicate that inhibition of sclerostin may elevate cardiovascular risk, warranting a rigorous evaluation of the cardiovascular safety of romosozumab and other sclerostin inhibitors.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Bovijn J, Krebs K, Chen CY, et al. Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. 2020. PMID: 32581134. doi:10.1126/scitranslmed.aay6570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。